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ABSTRACT
C-X-C motif chemokine receptor 4 (CXCR4) is a key factor for tumor growth and 
metastasis in several types of human cancer. This study investigated the feasibility of 
CXCR4-directed imaging with positron emission tomography/computed tomography 
(PET/CT) using [68Ga]Pentixafor in malignant pleural mesothelioma.
Six patients with pleural mesothelioma underwent [68Ga]Pentixafor-PET/
CT. 2′-[18F]fluoro-2′-deoxy-D-glucose ([18F]FDG)-PET/CT (4/6 patients) and 
immunohistochemistry obtained from biopsy or surgery (all) served as standards 
of reference. Additionally, 9 surgical mesothelioma samples were available for 
histological work-up. 
Whereas [18F]FDG-PET depicted active lesions in all patients,  [68Ga]Pentixafor-
PET/CT recorded physiologic tracer distribution and none of the 6 patients 
presented [68Ga]Pentixafor-positive lesions. This finding paralleled results of 
immunohistochemistry which also could not identify relevant CXCR4 surface 
expression in the samples analyzed. 
In contrast to past reports, our data suggest widely absence of CXCR4 expression 
in pleural mesothelioma. Hence, robust cell surface expression should be confirmed 
prior to targeting this chemokine receptor for diagnosis and/or therapy.
INTRODUCTION
Malignant pleural mesothelioma (PM) is a rare 
(incidence, 7/1.000.000/year) aggressive cancer associated 
with occupational exposure to asbestos that is often 
diagnosed at late, unresectable stages [1, 2]. Despite 
aggressive treatment algorithms including radiation and/
or chemotherapy, the prognosis of mesothelioma has 
remained poor for decades, with an average survival of 
9–12 months [3]. Therefore, new molecular targets for this 
fatal disease need to be identified.
C-X-C motif chemokine receptor 4 (CXCR4) and 
its ligand CXCL12 play an important role in a variety 
of physiological processes that rely on the recruitment 
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and homing of stem cells, progenitor cells and immune 
cells. CXCR4 is over-expressed in more than 20 human 
tumor types, promoting tumor growth and progression, 
tumor invasiveness and metastasis [4]. In malignant 
mesothelioma, robust overexpression of CXCR4 was 
reported in human mesothelioma cell lines and the 
majority of mesothelioma tissues, respectively [5]. 
Recently, Wester and co-workers developed [68Ga]
Pentixafor ([68Ga]CPCR4.2), a cyclic pentapeptide that 
enables sensitive and high-contrast imaging of human 
CXCR4 receptor expression in vivo [6–8] . Proof-of-
concept visualization with this tracer could be demonstrated 
for several different hematologic and other neoplasms 
including leukemia, lymphoma, multiple myeloma, 
glioblastoma or small cell lung cancer, but also in other 
(inflammatory) disease conditions, such as stroke and 
myocardial infarction [9–15].  Interestingly, in a pilot study, 
the in vitro CXCR4 expression profile of solid cancers 
was shown to be different from the in vivo distribution as 
revealed by CXCR4-targeted PET imaging [16].
The aim of this pilot study was to assess the 




Histopathologic diagnosis had been derived by 
surgical or biopsy samples in all patients. 4/6 patients 
suffered from epitheloid, the remaining subjects from 
desmoplastic/sarcomatoid and microcystic mesothelioma, 
respectively. All subjects presented with diseases confined 
to the mesothelial surfaces of the pleural cavity. No extra-
pleural metastatic sites were present at the time point of 
imaging (Supplementary Table 1). 
Surgical samples
The surgical samples available for IHC were 
derived from patients with epitheloid (n = 4), sarcomatoid 
(n = 3), and biphasic (n = 2) mesothelioma, respectively. 
All samples were derived from patients (8 males, 1 
female) with the primary diagnosis of PM. None of them 
presented with extra-pleural metastases.
Image analysis
On visual image analysis of the scans, none of the 
six patients presented relevant focal [68Ga]Pentixafor-
positive lesions (Figure 1). Only physiologic tracer 
distribution was recorded.  
In semi-quantitative analysis, SUVmean ranged from 
1.4 to 2.9 with a median of 2.5 and SUVmax from 2.3 to 
4.4 with a median of 3.9, respectively. Median blood 
pool activity was 1.8 (range, 1.6–2.7) for SUVmean and 3.6 
(range, 2.8–4.6) for SUVmax. Accordingly, tumor-to-blood 
pool (TBR) ratios were low in all cases with a median of 
1.2 (range, 0.9–1.6) for TBRmean and 1.0 for TBRmax (range, 
0.7–1.4), respectively. 
In contrast, [18F]FDG-PET identified viable tumor 
lesions in all patients with SUVmean  ranging from 5.8 to 
11.3 (median, 8.3) and SUVmax from 7.8 to 18.4 (median, 
11.5), respectively. With median blood pool uptake of 1.8 
(SUVmean, range, 1.7 to 2.2) and 2.7 (SUVmax, range, 2.0 to 
3.2), median TBRs were 4.9 (range, 2.9–5.1) for SUVmean 
and 5.2 (range, 2.5–5.8) for SUVmax, respectively. Results 
for each individual patient are mentioned in Table 1.
Immunohistochemistry
In all patients, imaging results could be compared 
to CXCR4 expression in biopsies or surgical specimens 
of the primary tumors assessed by immunohistochemistry. 
Regarding the histological evaluation of membranous 
CXCR4 expression, none of samples revealed specific 
staining for the chemokine receptor (Figure 2). 
Nine additional surgical mesothelioma samples from 
patients not undergoing CXCR4-directed imaging were 
available for analysis. In parallel with the findings for the 
patients in whom imaging was performed, all samples 
were negative for CXCR4 expression in IHC. 
DISCUSSION
This is the first report of in vivo imaging of CXCR4 
expression in humans with pleural mesothelioma. Whereas 
a first study on malignant mesothelioma cells (derived 
from pleural effusions) showed an infrequent chemokine 
receptor expression [17], a recent report evaluating 
mesothelioma cell lines and biopsy samples demonstrated 
a robust CXCR4 receptor expression in malignant PM 
[5]. Strikingly, IHC for CXCR4 was principally positive 
in 5 of 6 human mesothelioma cell lines as well as 31/41 
mesothelioma tissues. Almost 40% of patient samples 
demonstrated strong chemokine receptor expression as 
determined by IHC.
In contrast, in our cohort of PM patients and 
mesothelioma samples, no significant receptor expression 
was identified, neither by PET/CT imaging nor 
immunohistochemical staining. Of note, in the cases with 
corresponding [18F]FDG-PET/CT serving as reference, 
all tumor lesions exhibited intense FDG uptake (as a 
marker of tumor viability) with high tumor-to-background 
ratios. Thus, our findings are in line with a previous study 
reporting on a rather lower CXCR4 expression profile of 
solid cancers and metastases (not including mesothelioma) 
in vivo [16]. The reason for this obvious discrepancy to the 
past series is unclear. As a potential explanation, one might 
argue that cell lines do not fully represent in vivo disease, 
e.g. due to the lack of the tumor microenvironment. The 
differences in tissue samples might be explained by 
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the fact that receptor surface expression of CXCR4 is 
a dynamic process which is influenced by a number of 
factors including therapeutic agents. However, in IHC 
analyses we did not only find no CXCR4 at the cell surface 
but also no evidence/indication of intracellular CXCR4 
protein expression. In our small cohort, all patients were 
treatment-naïve at the time of both imaging and biopsy/
surgery. Though Li et al. report that all patients´ samples in 
their study were directly obtained from surgery we cannot 
exclude the possibility of altered CXCR4 expression due 
to potential previous therapies. Future studies to further 
investigate therapy-induced down- and –preferably- up-
regulation of CXCR4 are highly warranted.
In cell culture experiments, Li and co-workers could 
also demonstrate that CXCL12, the sole ligand of CXCR4, 
can induce proliferation in mesothelioma which can be 
antagonized by administration of CXCR4 inhibitors such 
as AMD3100 [5]. Given the high cellular expression of 
the chemokine receptor in vitro as well as the effects of 
CXCR4 inhibition, the authors concluded that CXCR4-
directed therapies might prove beneficial in high-expressing 
tumors. Since the advent of [68Ga]Pentixafor and its 
therapeutic counterpart, [90Y]/[177Lu]Pentixather, theranostic 
concepts for CXCR4 have successfully introduced by 
nuclear medicine [18]. Given the high receptor expression 
previously described, we hypothesized that malignant 
Table 1: Individual imaging results
No. Age Sex [68Ga]Pentixafor [18F]FDG
SUVmean SUVmax TBRmean TBRmax SUVmean SUVmax TBRmean TBRmax
1 54 M 2.3 4.4 1.3 1.0 n/a n/a n/a n/a
2 69 F 2.7 3.9 1.6 1.3 8.0 11.0 4.8 5.4
3 60 M 1.4 2.3 0.9 0.7 8.6 12.0 5.0 5.0
4 78 M 2.5 3.9 1.1 1.0 n/a n/a n/a n/a
5 73 M 2.9 3.6 1.1 0.9 5.8 7.8 3.0 2.5
6 80 M 2.5 3.8 1.6 1.4 11.3 18.4 5.1 5.8
n/a = not available.
Figure 1: Example of epitheloid mesothelioma (patient #3) without relevant CXCR4 expression. Maximum intensity 
projections (outer columns) and transaxial slices (middle column) of [18F]FDG PET/CT (left, upper row of the middle column) and [68Ga]
Pentixafor PET/CT (right, lower row of middle column) in a patient with the primary diagnosis of epitheloid mesothelioma. The multiple 
vital tumor lesions along the right pleura detected by [18F]FDG PET/CT (arrows) do not express CXCR4. This finding was confirmed by 
immunohistochemistry.
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mesothelioma might represent an attractive target for 
endoradiotherapy. However, based on our results, CXCR4 
does not seem a promising therapeutic option for patients 
with progressive, irresectable or chemo-refractory disease. 
Limitations of the study include that –also due 
to the low incidence of mesothelioma- only a limited/
small number of patients could be included in the study. 
Therefore, all conclusions have to be drawn with caution, 
also given the fact that almost all patients and 4/9 
samples included in our study represented the epitheloid 
subtype. Thus, potentially differential CXCR4 expression 
by different histologic mesothelioma subtypes (e.g. 
sarcomatoid mesothelioma) might have been missed.
Furthermore, biopsies were not always obtained on 
a short-term period compared to the time point of PET 
imaging. However, the maximum interval between imaging 
and biopsy was 4 weeks with no treatment administered 
in between. Thus, we are convinced that therapy-induced 
changes in receptor expression can be ignored.
To conclude, our data suggest a lower frequency 
of CXCR4-positivity than previously reported. Prior 
to targeting this chemokine receptor for therapy, 
robust cell surface expression should be confirmed by 
immunohistochemistry of the tumor sample, or whole-
body [68Ga]Pentixafor-PET/CT.
MATERIALS AND METHODS
Subjects and research design
Six patients (5 males, 1 female, age 54–80 y; mean, 
69 ± 10 y) with histologically proven primary diagnosis of 
pleural mesothelioma were enrolled. 
At the time point of imaging, all patients were 
treatment-naïve. PET scans were performed for staging 
purposes ([18F]FDG) and to measure the expression of 
CXCR4 ([68Ga]Pentixafor) as a potential therapeutic 
target for a beta-emitter linked analog. After imaging, 
surgery was performed in all patients. In five subjects, 
external beam radiation was performed after the surgical 
procedure. Two patients also received (platinum-based) 
chemotherapy. Checkpoint inhibitors were administered 
in one patient. Detailed patient characteristics are given in 
Supplementary Table 1.
[68Ga]Pentixafor was administered in compliance with 
The German Medicinal Products Act, AMG §13 2b, and in 
accordance with the responsible regulatory body (Regierung 
von Oberfranken). The data analysis was disclosed to the 
ethics committee of the Universitätsklinikum Würzburg and 
the need of a formal review was waived. All patients signed 
written informed consent prior to imaging.
Surgical mesothelioma samples
In addition to the samples available from the patients 
undergoing imaging, 9 surgical mesothelioma samples 
were available for histological analysis. 
Preparation of [18F]FDG and the chemokine 
receptor CXCR4 targeting probe [68Ga]
Pentixafor
[18F]FDG was synthesized in house with a 16 MeV 
Cyclotron (GE PETtrace 6; GE Healthcare, Milwaukee, 
USA) using GE FASTlab methodology according to the 
manufacturer’s instructions. 
Figure 2: Individual IHC results for CXCR4. Display of the individual results of immunohistochemistry (IHC) for the six patients 
undergoing [68Ga]Pentixafor-PET/CT. In parallel to imaging, no significant CXCR4 expression could be demonstrated on the tumor cell 
surface. Vascular epithelium served as internal and adrenocortical tissue as external control. Magnification: ×400.
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Synthesis of [68Ga]Pentixafor was performed in 
a fully automated, GMP-compliant procedure using a 
GRP® module (SCINTOMICS GmbH, Fürstenfeldbruck, 
Germany) connected to a 68Ge/68Ga-generator (Eckert und 
Ziegler, Berlin, Germany) and equipped with a disposable 
single-use cassette kit (ABX, Radeberg, Germany), using 
the standardized labelling sequence previously described 
[19] and 20 µg of unlabelled Pentixafor (SCINTOMICS 
GmbH). Before use, the radiopharmaceutical was 
analyzed according to the monographs 2462 (Gallium 
Chloride) and 2482 (Gallium Edotreotide) of the European 
Pharmacopoeia. The radiochemical purity was the tracer 
was > 98% with a specific activity greater than 5 MBq/µg.
PET imaging 
All [68Ga]Pentixafor and [18F]FDG-PET/CT scans 
were performed on a dedicated PET/CT scanner (Siemens 
Biograph mCT 64; Siemens Medical Solutions, Erlangen, 
Germany) after a 4 hour fasting period. For [68Ga]
Pentixafor PET, injected activity ranged from 78 to 142 
MBq (mean, 123±26 MBq). For standard [18F]FDG-PET 
which was available in 4/6 patients, 287 ± 22 MBq were 
administered.
Low dose CT scans for attenuation correction were 
acquired (35 mAs, 120 keV, a 512 × 512 matrix, 5 mm 
slice thickness with a total of 201 slices, increment of 
30 mm/s, rotation time of 0.5 s, and pitch index of 0.8). 
The imaging field ranged from the base of the skull to the 
proximal thighs. 
Whole-body scans encompassing 6–7 bed 
positions were performed 1h after administration of the 
radiopharmaceutical. All PET images were reconstructed 
using corrections for attenuation, dead-time, random 
events and scatter. The PET scanner is periodically 
checked for calibration accuracy as part of quality control 
according to published guidelines [20].
Image analysis
Images were visually analyzed by two experienced 
nuclear medicine specialists (C.L., K.H.). Tumor regions of 
interest (ROIs) were defined by drawing a standardized 10-
mm circular region over the area with the peak tumor activity. 
Maximum (SUVmax) and mean standardized uptake values 
(SUVmean) were derived. A reference region was defined by 
drawing a ROI (diameter of 25 mm) in the cavity of the right 
ventricle of the heart. The radiotracer concentration in the 
ROIs was normalized to the injected dose per kilogram body 
weight of patient to derive the SUVs.
CXCR4 immunohistochemistry (IHC)
Immunohistochemical analysis of CXCR4 
expression was performed on paraffin sections (1 µm) 
derived from biopsies of the primary tumor using an anti-
CXCR4 rabbit polyclonal antibody (ab2074; Abcam, 
Cambridge, UK) and the DAKO en vision system. For 
evaluation, the immune reactive score – based on the 
percentage of CXCR4-positive cells multiplied with 
the staining intensity- was calculated[12]. CXCR4 
positivity of vascular epithelium served as internal 
and adrenocortical tissue as external positive control, 
respectively [21–23]. Biopsies were obtained within 4 
weeks before/after [68Ga]Pentixafor-PET/CT examinations 
(mean, 20 ± 7 days). In the interval between biopsy/
surgery and imaging, no treatment for mesothelioma was 
administered. 
Ethical approval
All procedures performed in studies involving 
human participants were in accordance with the 1964 
Helsinki declaration and its later amendments or 
comparable ethical standards. [68Ga]Pentixafor was 
administered in compliance with The German Medicinal 
Products Act, AMG §13 2b, and in accordance with the 
responsible regulatory body (Regierung von Oberfranken). 
The data analysis was disclosed to the ethics committee 
of the Universitätsklinikum Würzburg and the need of a 
formal review was waived.
Informed consent
Informed consent was obtained from all individual 
participants included in the study.
ACKNOWLEDGMENTS
We thank Simone Seifert, Michael Schulze-Glück 
(members of the nuclear medicine PET team) and Christa 
Albert for their support and assistance.
CONFLICTS OF INTEREST
HJW is founder and shareholder of Scintomics. SKr 
is CEO of Scintomics. All other authors declare no conflict 
of interest.
FUNDING
This paper was supported by the University of 
Wuerzburg as part of the funding program Open Access 
Publishing.
REFERENCES
1. Bueno R. Mesothelioma clinical presentation. Chest. 1999; 
116:444S–445S.
2. Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. US 
mesothelioma patterns 1973-2002: indicators of change and 
Oncotarget96737www.impactjournals.com/oncotarget
insights into background rates. Eur J Cancer Prev. 2008; 
17:525–534.
 3. Marinaccio A, Binazzi A, Bonafede M, Corfiati M, Di 
Marzio D, Scarselli A, Verardo M, Mirabelli D, Gennaro V, 
Mensi C, Schallemberg G, Merler E, Negro C, et al, and 
ReNaM Working Group. Malignant mesothelioma due to 
non-occupational asbestos exposure from the Italian national 
surveillance system (ReNaM): epidemiology and public health 
issues. Occup Environ Med. 2015; 72:648–655.
 4. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-
Bosscha H, Huls G, de Vries EG, Walenkamp AM. A review 
on CXCR4/CXCL12 axis in oncology: no place to hide. Eur 
J Cancer. 2013; 49:219–230.
 5. Li T, Li H, Wang Y, Harvard C, Tan JL, Au A, Xu Z, 
Jablons DM, You L. The expression of CXCR4, CXCL12 
and CXCR7 in malignant pleural mesothelioma. J Pathol. 
2011; 223:519–530.
 6. Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ. 
PET imaging of CXCR4 receptors in cancer by a new 
optimized ligand. ChemMedChem. 2011; 6:1789–1791.
 7. Gourni E, Demmer O, Schottelius M, D’Alessandria C, 
Schulz S, Dijkgraaf I, Schumacher U, Schwaiger M, 
Kessler H, Wester HJ. PET of CXCR4 expression by a (68)
Ga-labeled highly specific targeted contrast agent. J Nucl 
Med. 2011; 52:1803–1810.
 8. Herrmann K, Lapa C, Wester HJ, Schottelius M, 
Schiepers C, Eberlein U, Bluemel C, Keller U, 
Knop S, Kropf S, Schirbel A, Buck AK, Lassmann M. 
Biodistribution and radiation dosimetry for the chemokine 
receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl 
Med. 2015; 56:410–416.
 9. Wester HJ, Keller U, Schottelius M, Beer A, Philipp-
Abbrederis K, Hoffmann F, Simecek J, Gerngross C, 
Lassmann M, Herrmann K, Pellegata N, Rudelius M, 
Kessler H, Schwaiger M. Disclosing the CXCR4 expression 
in lymphoproliferative diseases by targeted molecular 
imaging. Theranostics. 2015; 5:618–630.
10. Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, 
Eiber M, Luckerath K, Pietschmann E, Habringer S, 
Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, 
et al. In vivo molecular imaging of chemokine receptor 
CXCR4 expression in patients with advanced multiple 
myeloma. EMBO Mol Med. 2015; 7:477–487.
11. Lapa C, Schreder M, Schirbel A, Samnick S, Kortum KM, 
Herrmann K, Kropf S, Einsele H, Buck AK, Wester HJ, 
Knop S, Luckerath K. [68Ga]Pentixafor-PET/CT for 
imaging of chemokine receptor CXCR4 expression 
in multiple myeloma - Comparison to [18F]FDG and 
laboratory values. Theranostics. 2017; 7:205–212.
12. Lapa C, Luckerath K, Kleinlein I, Monoranu CM, 
Linsenmann T, Kessler AF, Rudelius M, Kropf S, Buck AK, 
Ernestus RI, Wester HJ, Lohr M, Herrmann K. (68)Ga-
Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 
Expression in Glioblastoma. Theranostics. 2016; 6:428–434.
13. Lapa C, Luckerath K, Rudelius M, Schmid JS, Schoene A, 
Schirbel A, Samnick S, Pelzer T, Buck AK, Kropf S, 
Wester HJ,Herrmann K. [68Ga]Pentixafor-PET/CT for 
imaging of chemokine receptor 4 expression in small cell lung 
cancer - initial experience. Oncotarget. 2016; 7:9288–9295. 
https://doi.org/10.18632/oncotarget.7063.
14. Lapa C, Reiter T, Werner RA, Ertl G, Wester HJ, Buck AK, 
Bauer WR, Herrmann K. [(68)Ga]Pentixafor-PET/CT 
for Imaging of Chemokine Receptor 4 Expression After 
Myocardial Infarction. JACC Cardiovasc Imaging. 2015; 
8:1466–1468.
15. Schmid JS, Schirbel A, Buck AK, Kropf S, Wester HJ, 
Lapa C. [68Ga]Pentixafor-Positron Emission Tomography/
Computed Tomography Detects Chemokine Receptor 
CXCR4 Expression After Ischemic Stroke. Circ Cardiovasc 
Imaging. 2016; 9:e005217.
16. Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-
Abbrederis K, Graner FP, Ettl J, Keller U, Wester HJ, 
Schwaiger M. First Experience with Chemokine Receptor 
CXCR4-Targeted PET Imaging of Patients with Solid 
Cancers. J Nucl Med. 2016; 57:741–746.
17. Davidson B, Dong HP, Holth A, Berner A, Risberg B. 
Chemokine receptors are infrequently expressed in 
malignant and benign mesothelial cells. Am J Clin Pathol. 
2007; 127:752–759.
18. Herrmann K, Schottelius M, Lapa C, Osl T, 
Poschenrieder A, Hanscheid H, Luckerath K, Schreder M, 
Bluemel C, Knott M, Keller U, Schirbel A, Samnick S, 
et al. First-in-Human Experience of CXCR4-Directed 
Endoradiotherapy with 177Lu- and 90Y-Labeled 
Pentixather in Advanced-Stage Multiple Myeloma with 
Extensive Intra- and Extramedullary Disease. J Nucl Med. 
2016; 57:248–251.
19. Martin R, Juttler S, Muller M, Wester HJ. Cationic eluate 
pretreatment for automated synthesis of [68Ga] CPCR4.2. 
Nucl Med Biol. 2014; 41:84–89.
20. Boellaard R, Hristova I, Ettinger S, Stroobants S, Chiti 
A, Bauer A, Tatsch K, Bourguet P, Bean J, Oyen W. Initial 
experience with the EANM accreditation procedure of FDG 
PET/CT devices. Eur J Cancer. 2011; 47:S8.
21. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM. 
Chemokine receptors in human endothelial cells. Functional 
expression of CXCR4 and its transcriptional regulation by 
inflammatory cytokines. J Biol Chem. 1998; 273:4282–4287.
22. Molino M, Woolkalis MJ, Prevost N, Pratico D, 
Barnathan ES, Taraboletti G, Haggarty BS, Hesselgesser 
J, Horuk R, Hoxie JA, Brass LF. CXCR4 on human 
endothelial cells can serve as both a mediator of biological 
responses and as a receptor for HIV-2. Biochim Biophys 
Acta. 2000; 1500:227–240.
23. Fischer T, Nagel F, Jacobs S, Stumm R, Schulz S. 
Reassessment of CXCR4 chemokine receptor expression in 
human normal and neoplastic tissues using the novel rabbit 
monoclonal antibody UMB-2. PLoS One. 2008; 3:e4069.
